KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBT (2016 - 2025)

Rigel Pharmaceuticals has reported EBT over the past 16 years, most recently at $22.7 million for Q4 2025.

  • For Q4 2025, EBT rose 49.22% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $121.8 million, up 563.33%, while the annual FY2025 figure was $121.8 million, 563.33% up from the prior year.
  • EBT for Q4 2025 was $22.7 million at Rigel Pharmaceuticals, down from $27.6 million in the prior quarter.
  • Over five years, EBT peaked at $60.0 million in Q2 2025 and troughed at -$27.4 million in Q1 2022.
  • A 5-year average of $2.0 million and a median of -$3.4 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: tumbled 166.5% in 2022 and later soared 5923.5% in 2025.
  • Year by year, EBT stood at -$22.7 million in 2021, then skyrocketed by 106.17% to $1.4 million in 2022, then crashed by 47.39% to $737000.0 in 2023, then surged by 1965.4% to $15.2 million in 2024, then surged by 49.22% to $22.7 million in 2025.
  • Business Quant data shows EBT for RIGL at $22.7 million in Q4 2025, $27.6 million in Q3 2025, and $60.0 million in Q2 2025.